Trial Profile

A phase I study assessing dexmedetomidine in Alzheimer's Disease patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Agitation
Focus Proof of concept; Therapeutic Use

Most Recent Events

16 Oct 2019 New trial record
03 Jan 2019 According to a BioXcel Therapeutics media release, this study along with a previous study in healthy volunteers(313833), as well as previously completed Phase 1 study (313819),provides a strong rationale to launch a potential registration trial of BXCL501.
03 Jan 2019 Primary endpoint Arousable sedation (RASS score of -1) has been met, according to the BioXcel Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com